Morning Brief — July 23, 2026

Market Overview

Futures are under pressure this morning as Alphabet and Tesla’s post-market earnings reignited AI capex spending fears, with GOOGL’s aggressive 2026 spending outlook spooking growth investors who had priced in discipline. Adding to the risk-off tone, oil prices have surged past $90/barrel on expanding Middle East conflict potentially threatening Red Sea shipping lanes, which simultaneously boosts energy names while hammering consumer discretionary and growth. The CRO/life sciences space is the notable counterweight — TMO, DGX, ICLR, and IQV are all catching bids on strong earnings, suggesting institutional rotation into beaten-down healthcare infrastructure names.

Claude’s Call

DOWN — The combination of GOOGL/TSLA earnings-driven capex anxiety and oil spiking through $90 on geopolitical escalation creates a dual headwind that the life sciences beat alone cannot offset; expect the S&P 500 to test the 20d low range with tech leading lower and energy/healthcare providing partial cushion, net negative on the day.

Top Movers

NVCR (+28.0%) — $19.93 → $22.55 (+8.1% upside) Thesis: Record Q2 revenue and active patient levels with a meaningful EPS beat (+56.7% surprise) and raised full-year revenue and adjusted EBITDA guidance — this is a clean, company-specific catalyst, not noise. The recent EU approval of Optune Pax for pancreatic cancer adds a genuine pipeline expansion story. Technically, NVCR is sitting right at its 6-month high, which is also the 20-day high — this is a fresh breakout rather than a continuation, which is more compelling. That said, the RSI at 68 and the stock already touching new highs means there’s limited margin of error; any guidance nuance re-read could pull it back. Levels: Exit at fib extension 1.272 at $22.55. Support at fib 23.6% retracement at $17.55, with the 50-SMA at $16.73 as the deeper floor.

MEDP (+22.48%) — $646.83 → $716.90 (+10.8% upside) Thesis: This is a genuine earnings recovery story — MEDP beat on revenue (+1.12% surprise), posted EPS 4.17% above consensus, and critically delivered a bookings beat that reversed Q1’s malaise. The book-to-bill recovery is the KEY metric here; after a 0.88x B2B in Q1 sent the stock to nine-month lows, a rebound signals pipeline normalization in the CRO space. Revenue up 17.2% YoY with full-year guidance raised to $2.85B (2.6% above consensus) — this is a company re-establishing credibility. RSI at 28 is technically oversold on a weekly basis even after today’s surge, which tells you how punished this name was — the bounce has room. Breaking out above the prior 6-month high with the SMA-50 at $485 far below. Levels: Exit at fib 1.272 extension at $716.90. Support at fib 23.6% at $587.71; the 50-SMA at $485 is the structural floor if the recovery thesis cracks.

SMCI (+19.84%) — $30.56 → $35.35 (+15.6% upside) Thesis: A record $60 billion backlog with raised gross margin guidance — this is real AI infrastructure demand, not hype. SMCI is benefiting directly from Nvidia-powered server demand, and the backlog figure is a forward-looking demand signal that consensus models likely haven’t fully absorbed. The stock is a direct “picks and shovels” beneficiary of the AI capex boom — ironically, the same GOOGL/TSLA capex spending that’s worrying the market is precisely what fills SMCI’s order book. Technically, the stock is trading just below the 50-SMA at $32.79 and just under the fib 61.8% retracement at $31.85 from the 6-month swing. Reclaiming $32.79 (the SMA) on a closing basis would be the technical confirmation bulls need. Levels: Exit target at fib 50% retracement at $35.35 (from the 6-month range). Support at 20-day low of $23.83; be cautious if $30 breaks intraday.

ARWR (+19.03%) — $88.70 → $97.86 (+10.3% upside) Thesis: Plozasiran delivered best-case scenario data in TWO late-stage trials — triglyceride reduction of up to 81% vs. 27% for placebo. This isn’t a Phase 1 press release; this is pivotal data that clears the bar for an FDA submission by year-end. Chardan raised the PT to $115 from $90. This is a clinical-stage biotech hitting its biggest catalyst, and management is moving straight to the sNDA filing — execution risk is now regulatory, not scientific. The stock is at a 5-year high, consolidating just below the 6-month high. The valuation comps flag it as “CHEAP” on a relative basis (negative PE, pre-commercial), but the relevant peer comp is the specialty cardiology/lipid space, and with an sNDA coming, the re-rating is toward commercial-stage multiples. Volume is whisper-thin (vol_ratio 0.02) — that’s a concern; this move needs follow-through volume to be sustained. Levels: Exit at fib 1.272 extension at $97.86. Support at fib 23.6% at $80.75; below that, $75.83 (38.2%) is the line in the sand.

CLF (+13.97%) — $10.77 → $11.46 (+6.4% upside near-term) Thesis: A slight Q2 EPS miss was overwhelmed by a stronger-than-expected Q3 EBITDA outlook — investors are forward-looking, and CLF is telling the market profitability is inflecting upward. The tariff environment and any domestic steel demand recovery are structural tailwinds for this integrated steel producer. However, this is a deeply cyclical name that was down 31.76% YTD before today — you’re catching a falling knife on a guidance beat, not a structural turn. The stock is now testing the 50-SMA at $11.25 from below, which is the critical near-term hurdle. I’d want to see a close above $11.25 before getting excited. Levels: Exit at fib 50% retracement at $11.46 (from 6-month range). Support at $10.60 (fib 61.8%); below that, you’re back toward the 6-month low at $7.82.

PAG (+9.93%) — $214.57 → $235.02 (+9.5% upside to arb ceiling) Thesis: Penske Corporation and Mitsui bid $210/share to take Penske Automotive private. This is a controlling shareholder buyout — meaning minority investors face a take-it-or-leave-it dynamic at $210. The stock at $214.57 is already trading through the $210 bid, implying either the market expects a bump or arbitrageurs are pricing in a sweetened offer. With the 6-month high at $214.57, the stock is right at its recent ceiling. Be careful: the fib 1.272 extension is at $235.02, but that’s only realistic if a competing bid emerges — which is structurally unlikely given the controlling shareholder dynamic. This is an event-driven arb, not a momentum trade. The risk is the deal closes at $210 and you bought at $214. Levels: Arb ceiling likely near $210-$225 range depending on bump probability. Support at $196.83 (fib 23.6%) if deal falls through.

TMO (+9.38%) — $575.84 → $676.37 (+17.5% upside) Thesis: EPS beat by 5.6%, revenue beat by 2.67%, improving customer demand across end markets — this is the life sciences infrastructure recovery trade in one stock. RSI at 14.06 is extraordinarily oversold, meaning institutional money is stepping into a quality name that had been punished. With the 50-SMA at $489.67 already broken to the upside and the stock bouncing from deeply oversold territory, this is the definition of a quality dip into a catalyst event. The question is whether the broader risk-off environment today (oil, GOOGL capex fears) caps near-term upside. Levels: Exit at fib 1.272 extension at $676.37. Immediate support at fib 23.6% at $581.13 (just above current price — watch this closely). Deeper support at 38.2% fib at $553.76 and SMA-50 at $489.67.

DGX (+8.79%) — $228.28 → $246.27 (+7.9% upside) Thesis: Quest beat on both revenue (+2.15%) and EPS (+11.03% — non-GAAP $3.12 vs. consensus), with revenue up 10.2% YoY to $3.04B. AI-assisted diagnostics and broad channel strength across physician, hospital, and consumer segments are the structural story. RSI at 12.11 is the most oversold reading on today’s entire list — this stock was priced for disaster and delivered solid execution. At a 6-month high with the SMA-50 at $201.14 far below, DGX is confirming a technical breakout backed by fundamental catalysts. This is one of the cleanest setups in today’s session. Levels: Exit at fib 1.272 extension at $246.27. Support at fib 23.6% at $219.60; the SMA-50 at $201.14 is the structural support if sentiment reverses.

IQV (+8.35%) — $215.09 → $263.99 (+22.7% upside) Thesis: IQVIA reports next week, but it’s getting a sympathy lift from the CRO sector recovery trade (MEDP beat, ICLR strength) today. RSI at 12.26 is extreme oversold territory — the market had priced catastrophe into CRO names, and MEDP’s bookings recovery is signaling the worst may be behind the sector. The Artisan Partners position initiation citing AI resilience is the fundamental backstory. This is partially sector sympathy (weakness of a catalyst) but with a real earnings catalyst one week away. Be aware: pre-earnings run-ups in CRO names can reverse hard on the actual print if guidance disappoints again. Levels: Exit at fib 1.272 extension at $263.99 (aggressive; more conservative target is $221 fib resistance). Support at fib 38.2% at $208.81 and SMA-50 at $187.02.

EQT (+8.45%) — $54.01 → $56.07 (+3.8% near-term) Thesis: EQT missed on Q2 earnings AND revenues, but raised production guidance and reduced capex — the market is buying the forward story, not the backward print. The natural gas supply squeeze narrative for AI data centers is gaining traction (Microsoft, Amazon data center power demand), and EQT is the premier natural gas producer positioned to benefit. The SMA-50 at $53.07 is providing immediate support with the stock just above it. However, this is a momentum play on a narrative, not a fundamentals beat — and oil at $90 (Brent) with a geopolitical escalation backdrop could be the tailwind that sustains it. Levels: Exit at fib 61.8% retracement at $56.07 (from 6-month range). Support at SMA-50 at $53.07 and 20-day low of $48.85.

Headlines to Watch

“Dow Jones Futures Fall As Oil Prices Top $90; Google, Tesla Skid On Earnings, Capital Spending” — Alphabet’s capex hike is the single most important macro signal today: if the AI infrastructure buildout is accelerating, it’s bullish for SMCI/NVDA but bearish for GOOGL on margin compression fears; position accordingly.
“Penske, Mitsui Bid $210 Per Share to Take Penske Automotive Group Private” — With PAG trading above the $210 bid at $214.57, the market is pricing a bump; pure arb play but the controlling shareholder structure severely limits competing bid probability — trim if you’re above $215.
“Arrowhead Shares Soar on Strong Triglyceride Drug Data” — Plozasiran’s 81% triglyceride reduction in two Phase 3 trials clears the bar for FDA submission; watch for cardiovascular majors (Novartis, Pfizer, Alnylam) as potential acquirers — this data makes ARWR a legitimate M&A target.
“Supermicro Stock Jumps on Gross Margin Raise Amid Record $60 Billion Backlog” — SMCI’s backlog is a real-time demand signal for AI server infrastructure; if GOOGL’s capex hike is the fear, SMCI’s backlog is the offsetting proof — AI buildout spending is not slowing, it’s accelerating.
“Cleveland-Cliffs Shares Jump as Upbeat Q3 Forecast Outweighs Earnings Miss” — CLF’s Q3 EBITDA guidance beat is the first sign of steel profitability recovery; watch domestic auto production and infrastructure spending data as the catalyst for a sustained reversal or another head-fake.
“Middle East Conflict Expands to Potentially Include Red Sea” — Oil at $90 is the macro wildcard; Red Sea disruption historically adds 2-4% to shipping costs and boosts energy stocks (EQT, TTE, EQNR) while pressuring consumer discretionary and global supply chains — this is the tail risk that can cascade.
“NovoCure’s Cancer Treatment Device Option Pax Gets European Approval” — EU approval for pancreatic cancer treatment Optune Pax is a multi-year revenue expansion opportunity in a historically underserved indication; combined with today’s Q2 beat and guidance raise, NVCR’s product portfolio diversification story is finally materializing.

Claude’s Top Picks

DGX (+8.79% today, +9.01% week) — $228.28 → $246.27 (+7.9% upside) Valuation: DGX trades at a reasonable forward multiple for a diagnostics compounder, and with the SMA-50 at $201 well below current price, institutional accumulation is confirmed. Upside: RSI at 12 (most oversold on the entire list) into a clean double-beat on earnings — this is the textbook oversold quality bounce with fundamental backing; the fib 1.272 extension at $246.27 is achievable within 1-2 weeks. Risk: Broader healthcare policy risk (Medicaid reimbursement, drug pricing legislation) and a risk-off tape today driven by oil/tech could temporarily cap upside even with a strong print.

MEDP (+22.48% today, +20.25% week) — $646.83 → $716.90 (+10.8% upside) Valuation: No comps data provided, but MEDP’s 17.2% revenue growth and raised full-year guidance justify a premium CRO multiple; the prior nine-month low was a significant value dislocation relative to growth profile. Upside: The bookings recovery (book-to-bill reversal from 0.88x) is the signal the CRO sector’s demand trough may be behind us — MEDP is the cleanest expression of that thesis with company-specific confirmation, not just sector sympathy. Risk: RSI is climbing fast from oversold territory, and today’s 22% move means some fast-money buyers will take profits Friday; stop below fib 23.6% support at $587.71 if you enter above $640.

TMO (+9.38% today, +6.01% week) — $575.84 → $676.37 (+17.5% upside) Valuation: TMO is a best-in-class life sciences tools name with a historically premium multiple; after significant compression, the forward P/E is now at the lower end of its 5-year historical range, making valuation a tailwind. Upside: EPS beat of 5.6% + RSI at 14 (historically extreme oversold) + improving end-market demand = high-quality fundamental and technical setup; the SMA-50 at $489 confirms the stock has already made its structural low. Risk: Immediate resistance at the fib 23.6% level of $581.13 (just above current price) could cause short-term consolidation; also vulnerable to a broad market selloff today given GOOGL/oil headwinds.

ARWR (+19.03% today, +23.5% week) — $88.70 → $97.86 (+10.3% upside) Valuation: Flagged as CHEAP vs. peers on both forward P/E and EV/EBITDA (negative, pre-commercial), but the correct comp now is commercial-stage cardiovascular biotech; Chardan’s $115 PT implies significant re-rating room as the sNDA filing approaches year-end. Upside: Two pivotal trial wins in one press release with 81% triglyceride reduction vs. placebo is as clean a biotech catalyst as you get — FDA submission by year-end transforms this from clinical-stage to pre-commercial in 6 months, which is a material multiple expansion event. Risk: Volume is extremely thin (vol_ratio 0.02) — the move is happening on light volume which raises questions about sustainability; any FDA setback or delay to the sNDA timeline would be severely punished from current levels.

SMCI (+19.84% today, +13.65% week) — $30.56 → $35.35 (+15.6% upside) Valuation: No forward comps provided, but SMCI trades at a significant discount to its 6-month high of $50.17, and a $60B backlog implies revenue visibility that the current price does not fully reflect. Upside: $60B record backlog with gross margin guidance raised is the most concrete demand signal in AI hardware today — GOOGL’s capex hike is literally the customer spending that fills SMCI’s order book; the irony is that the same news hurting GOOGL is bullish for SMCI. Risk: The stock needs to reclaim the 50-SMA at $32.79 on a closing basis to confirm the reversal; SMCI has a history of sharp reversals on accounting/governance headlines, and today’s volume ratio of 0.17 suggests limited institutional conviction behind the move.

Avoid

FBRX (+11.63%, +28.27% week) — Trading at 6-month high of $56.94, up 263% from its 6-month low of $15.67; the vitiligo Phase 1b data is from a small placebo-controlled study, not a pivotal trial, and the SMA-50 at $25.75 is now nearly 55% below — this is a speculative biotech that has run massively on early-stage data with enormous pullback risk to fib 23.6% at $47.20 or lower.

NVCR (+28.0%) — While the earnings catalyst is real, NVCR is at its 6-month high with volume ratio of only 0.49 — the move is happening on below-average volume, which undermines the conviction of the breakout; chasing a 28% single-day move in a medical device company with no volume confirmation is dangerous, particularly with RSI at 68 and the nearest fib support (23.6%) already 12% below at $17.55.

TDTH (+7.83%) — A Chinese ADR trading at $3.03 with zero sector-specific catalyst (riding generic “Asian ADR” momentum), RSI at 18.77 is misleading in a micro-cap with a 6-month high of $10.86 and current price near multi-month lows; the vol_ratio of 0.00 means this is essentially untradeable with no liquidity — avoid entirely.

WSB Sentiment Check

GOOG — WSB says: BULLISH (80% bullish, 587 mentions, 7,106 upvotes) Claude says: DISAGREE — GOOGL is at its 6-month low of $321.82, having fallen from $402 highs, and the earnings catalyst just revealed aggressive capex that spooked the market; technically, the stock is at the fib 61.8% support ($322.63) which is the last line before a deeper breakdown — WSB is buying the dip on a name that just told the market it will sacrifice near-term margins for AI infrastructure, which is not a 1-2 week bullish catalyst.

MU — WSB says: MIXED (55% bullish, 366 mentions, 1,403 upvotes) Claude says: PARTIALLY AGREE — MU at $991 is trading near the fib 23.6% support at $1,002.95 after pulling back from $1,213 highs; the SMCI backlog signal is bullish for memory demand in AI servers, and the 50-SMA at $952 provides a floor; the mixed sentiment correctly reflects the tension between AI demand tailwinds and near-term margin uncertainty — a hold, not a strong buy today.

GOOGL — WSB says: BULLISH (80% bullish, 365 mentions, 4,098 upvotes) Claude says: DISAGREE — Same thesis as GOOG above; GOOGL is sitting exactly at fib 61.8% support ($322.63), which is technically the last support before a test of $273 (6-month low) — the capex overhang is real, the retail crowd is buying the dip on a name that’s in a technically precarious position; this is a hopium buy unless you see the AI capex as ultimately good for the ecosystem (which takes quarters, not days to play out).

SPCX — WSB says: BULLISH (80% bullish, 329 mentions, 1,727 upvotes) Claude says: DISAGREE — SPCX has crashed from $211.39 to $116.13 (6-month low) and is down 45% from peak; there’s no ticker-specific news in the data feed, and this smells like a meme pump on a beaten-down name; with no SMA-50 available and trading at a 6-month low with no discernible catalyst, this is the definition of a “dead cat bounce” — WSB piling in at the bottom of a 45% drawdown without a fundamental catalyst is a classic retail trap.

TSLA — WSB says: BULLISH (80% bullish, 313 mentions, 1,621 upvotes) Claude says: DISAGREE — TSLA is at its 6-month low of $334.41, down from $449 highs, with earnings just delivered that disappointed the market alongside heavy capex concerns; the 50-SMA at $405.26 is 21% above current price, meaning TSLA is in a confirmed downtrend; WSB’s 80% bullish read on a stock hitting new 6-month lows with negative earnings reaction is the classic retail “it’ll bounce back” mentality — the fib 61.8% support at $378.21 is nearly 13% above where it’s trading, meaning even the bears’ first target requires a significant rally; wait for stabilization.

Earnings Scorecard

TMO — BEAT by ~5.6% EPS, ~2.7% Revenue | Stock: +9.38% | Reported: Today (Before Open) Reaction is justified and possibly insufficient — an oversold quality name (RSI was at multi-year lows) beating across the board with improving end-market demand is a buy-the-dip moment that the 9% reaction barely begins to address; still a buy at current levels with room to fib 1.272 extension at $676.

RTX — BEAT (implied by headlines) | Stock: +6.89% | Reported: Today (Before Open) Raised full-year outlook with strong Q2 beat — reaction is justified; defense names are structural beneficiaries of geopolitical escalation (Middle East, Red Sea), making this a hold/add with the raised guidance as a catalyst; not a chase here but not a sell either.

TMUS — REPORTED | Stock: -6.4% | Reported: Yesterday (After Close) Mixed results with postpaid account additions declining — the market correctly punished this; T-Mobile’s growth narrative depends on subscriber adds, and declining postpaid accounts is the most important KPI going wrong; avoid until next quarter’s data.

EQNR — BEAT (implied, doubled buyback to $3B) | Stock: +3.1% | Reported: Yesterday Oil at $90 + $3B buyback announcement + earnings beat = reaction underwhelming; EQNR may be worth another look as an oil/geopolitical hedge with shareholder return acceleration — the 3.1% reaction seems insufficient for the quality of the news.

IBKR — BEAT (record Q2) | Stock: -2.99% | Reported: Yesterday Record earnings with crypto expansion — sold on the news; this is a classic “sell the rip” reaction where excellent results were already priced in; the -3% reaction on record earnings is a yellow flag — not a buy-the-dip, more of a “wait for washout.”

TXN — REPORTED (near-perfect earnings per headlines) | Stock: -2.83% | Reported: Yesterday (After Close) Near-perfect print but a warning for the chip sector per headlines — market is looking through the beat at forward inventory normalization concerns; sell-the-rip, not a buy.

SCCO — REPORTED | Stock: -2.56% | Reported: Yesterday Copper names selling despite solid results suggests industrial metals are pricing in demand concerns despite near-term beats; avoid.

TTE — BEAT (profit up 68%) | Stock: +2.56% | Reported: Yesterday Profit soaring 68% on oil price surge and the reaction was only +2.56% — significantly underwhelming given the magnitude of the earnings upside; TTE may actually be worth a look as an oil hedge against Middle East escalation risk with the market clearly not fully pricing the earnings recovery.

GEV — BEAT and raised guidance | Stock: +1.72% | Reported: Yesterday (After Close) Beat earnings AND raised guidance yet traded near flat — when a stock can’t rally on a beat-and-raise, the market is telling you the valuation is stretched; sell-the-rip, not a buy.

COF — BEAT on revenues, lower provisions | Stock: -1.54% | Reported: Yesterday Beat on the important metrics but Discover integration concerns are the overhang — neutral; hold existing positions, not a new entry point today.

AXP — REPORTED | Stock: -1.53% | Reported: Yesterday No specific beat/miss magnitude provided but mild selloff suggests in-line or slight miss; financial names are facing rising credit concerns in a high-rate environment — neutral to cautious.

MCO — STRONG BEAT ($13.91 EPS, strong revenue, raised guidance) | Stock: -1.73% | Reported: Yesterday Raised guidance on strong bond issuance activity yet down 1.73% — another “sell the rip” with valuation stretched; the bond issuance cycle has been the tailwind and the market may be concerned it’s peaking. Hold, don’t chase.

NOW — BEAT, raised subscription revenue forecast | Stock: -1.1% | Reported: Yesterday (After Close) ServiceNow raised guidance and beat, but the AI disruption fear narrative is creating a “prove it” moment for SaaS names despite strong results; reaction seems overdone to the downside — potential buy-the-dip for 1-2 week swing if the tape stabilizes.

PM — REPORTED (nicotine pouch rebound) | Stock: -1.43% | Reported: Yesterday Modest selloff on what sounds like a solid print with Zyn/nicotine pouch recovery; defensive name with a solid dividend — the -1.43% dip into a solid print looks like a buy for income-focused investors.

This brief is for informational purposes only and does not constitute financial advice. All technical levels are derived from the provided data. Past performance does not guarantee future results.